Floatz logo

Therapeutic Asset Ratings

184 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Ezabenlimab
triple-negative breast carcinoma
Institut BergoniéP2CCC (48)
Hyaluronidase zzxf
triple-negative breast carcinoma
Baylor Breast Care CenterP2CCC (48)
immunoglobulin G1-kappa, anti-[Homo sapiens TIGIT (T-cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV3-48*01 (90.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1-119) -Homo sapiens IGHG1*01, G1m17,1, G1v14 CH2 A1.3, A1.2 (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 L1.3>A (236), L1.2>A (237) (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (89.5%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in a Chinese hamster ovary (CHO)-K1 cell line, glycoform alfa
triple-negative breast carcinoma
MedSIRP2CCC (48)
Inbrx-106
triple-negative breast carcinoma
Providence Health & ServicesP2CCC (48)
Lifileucel
triple-negative breast carcinoma
M.D. Anderson Cancer CenterP2CCC (48)
Navicixizumab
triple-negative breast carcinoma
OncXerna Theraputics, Inc.P2CCC (48)
Ociperlimab
triple-negative breast carcinoma
Novartis PharmaceuticalsP2CCC (48)
sg001
triple-negative breast carcinoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.P2CCC (48)
SIMVASTATIN
triple-negative breast carcinoma
Indonesia UniversityP2CCC (48)
Tocilizumab
triple-negative breast carcinoma
Kathy MillerP2CCC (48)
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN) (HUMAN-MUS MUSCULUS MONOCLONAL CAN04 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CAN04 .KAPPA.-CHAIN, DIMER
triple-negative breast carcinoma
Cantargia ABP1/2CCC (48)
Sitravatinib
triple-negative breast carcinoma
Xiang ZhangP2CC (46)
cc-5013
triple-negative breast carcinoma
Andrew Hantel, MDP1/2CC (46)
DEXAMETHASONE
triple-negative breast carcinoma
Andrew Hantel, MDP1/2CC (46)
Obinutuzumab
triple-negative breast carcinoma
Simcha IL-18, Inc.P1/2CC (46)
n-803
triple-negative breast carcinoma
ImmunityBio, Inc.P2CC (45)
Seviteronel
triple-negative breast carcinoma
St Vincent's Hospital, SydneyP1/2CC (44)
Vidutolimod
triple-negative breast carcinoma
Regeneron PharmaceuticalsP2CC (43)
a2b395
triple-negative breast carcinoma
A2 Biotherapeutics Inc.P1/2CC (41)
ADG 106
triple-negative breast carcinoma
National University Hospital, SingaporeP1/2CC (41)
Apl-5125
triple-negative breast carcinoma
Apollo Therapeutics LtdP1/2CC (41)
azd6750
triple-negative breast carcinoma
AstraZenecaP1/2CC (41)
Blex 404
triple-negative breast carcinoma
BioLite, Inc.P1/2CC (41)
Cabiralizumab
triple-negative breast carcinoma
Washington University School of MedicineP1/2CC (41)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa
triple-negative breast carcinoma
Cancer Research UKP1/2CC (41)
Showing 76 to 100 of 184 assets
PreviousPage 4 of 8Next